Positron emission tomography tracers for synucleinopathies
Abstract Synucleinopathies, such as Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy, are characterized by the aggregation of α-synuclein. Variations in brain distribution allow for differentiation among these diseases and facilitate precise clinical diagnosis. However, di...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Molecular Neurodegeneration |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13024-024-00787-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544327103250432 |
|---|---|
| author | Jie Xiang Zhentao Zhang Shengxi Wu Keqiang Ye |
| author_facet | Jie Xiang Zhentao Zhang Shengxi Wu Keqiang Ye |
| author_sort | Jie Xiang |
| collection | DOAJ |
| description | Abstract Synucleinopathies, such as Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy, are characterized by the aggregation of α-synuclein. Variations in brain distribution allow for differentiation among these diseases and facilitate precise clinical diagnosis. However, distinguishing between synucleinopathies and Parkinsonism with tauopathies poses a challenge, significantly impacting clinical drug development. Therefore, molecular imaging is crucial for synucleinopathies, particularly for clinical diagnosis, assessment of drug efficacy, and disease surveillance. In recent years, advances in molecular imaging have led to rapid development of α-synuclein-specific tracers for positron emission tomography (PET), most of which are still in pre-clinical stages. Interestingly, some of these tracers share similar compound skeletal structures and are currently undergoing optimization for clinical application. Despite this progress, there remain challenges in developing α-synuclein tracers. This review summarizes recent findings on promising PET tracers and discusses representative compounds’ characteristics while offering suggestions for further research orientation. |
| format | Article |
| id | doaj-art-f054b88c664a45ba84d7cf762955453b |
| institution | Kabale University |
| issn | 1750-1326 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Neurodegeneration |
| spelling | doaj-art-f054b88c664a45ba84d7cf762955453b2025-01-12T12:39:42ZengBMCMolecular Neurodegeneration1750-13262025-01-012011910.1186/s13024-024-00787-9Positron emission tomography tracers for synucleinopathiesJie Xiang0Zhentao Zhang1Shengxi Wu2Keqiang Ye3Department of Neurobiology, Fourth Military Medical UniversityDepartment of Neurology, Renmin Hospital of Wuhan UniversityDepartment of Neurobiology, Fourth Military Medical UniversityFaculty of Life and Health Sciences, Shenzhen University of Advanced Technology (SUAT)Abstract Synucleinopathies, such as Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy, are characterized by the aggregation of α-synuclein. Variations in brain distribution allow for differentiation among these diseases and facilitate precise clinical diagnosis. However, distinguishing between synucleinopathies and Parkinsonism with tauopathies poses a challenge, significantly impacting clinical drug development. Therefore, molecular imaging is crucial for synucleinopathies, particularly for clinical diagnosis, assessment of drug efficacy, and disease surveillance. In recent years, advances in molecular imaging have led to rapid development of α-synuclein-specific tracers for positron emission tomography (PET), most of which are still in pre-clinical stages. Interestingly, some of these tracers share similar compound skeletal structures and are currently undergoing optimization for clinical application. Despite this progress, there remain challenges in developing α-synuclein tracers. This review summarizes recent findings on promising PET tracers and discusses representative compounds’ characteristics while offering suggestions for further research orientation.https://doi.org/10.1186/s13024-024-00787-9α-synucleinPositron emission tomography imagingTracer development |
| spellingShingle | Jie Xiang Zhentao Zhang Shengxi Wu Keqiang Ye Positron emission tomography tracers for synucleinopathies Molecular Neurodegeneration α-synuclein Positron emission tomography imaging Tracer development |
| title | Positron emission tomography tracers for synucleinopathies |
| title_full | Positron emission tomography tracers for synucleinopathies |
| title_fullStr | Positron emission tomography tracers for synucleinopathies |
| title_full_unstemmed | Positron emission tomography tracers for synucleinopathies |
| title_short | Positron emission tomography tracers for synucleinopathies |
| title_sort | positron emission tomography tracers for synucleinopathies |
| topic | α-synuclein Positron emission tomography imaging Tracer development |
| url | https://doi.org/10.1186/s13024-024-00787-9 |
| work_keys_str_mv | AT jiexiang positronemissiontomographytracersforsynucleinopathies AT zhentaozhang positronemissiontomographytracersforsynucleinopathies AT shengxiwu positronemissiontomographytracersforsynucleinopathies AT keqiangye positronemissiontomographytracersforsynucleinopathies |